Federal Register / Vol. 62, No. 47 / Tuesday, March 11, 1997 / Notices 11217

Contact Person: Dr. Peter R. Jackson,

Scientific Review Adm., 6003 Executive

Boulevard, Solar Bldg., Room 4C10,

Bethesda, MD 20892 (301) 496–2550.

Purpose/Agenda: To evaluate a grant

application.

Name of SEP: Expanded Research on

Emerging Diseases (Telephone Conference

Call).

Date: March 24, 1997.

Time: 2:30 p.m.

Place: Teleconference, 6003 Executive

Boulevard, Solar Bldg., Room 4C10,

Bethesda, MD 20892 (301) 496–2550.

Contact Person: Dr. Peter R. Jackson,

Scientific Review Adm., 6003 Executive

Boulevard, Solar Bldg., Room 4C10,

Bethesda, MD 20892 (301) 496–2550.

Purpose/Agenda: To evaluate a grant

application.

Name of SEP: Expanded Research on

Emerging Diseases (Telephone Conference

Call).

Date: March 24, 1997.

Time: 4:00 p.m.

Place: Teleconference, 6003 Executive

Boulevard, Solar Bldg., Room 4C10,

Bethesda, MD 20892 (301) 496–2550.

Contact Person: Dr. Peter R. Jackson,

Scientific Review Adm., 6003 Executive

Boulevard, Solar Bldg., Room 4C10,

Bethesda, MD 20892 (301) 496–2550.

Purpose/Agenda: To evaluate a grant

application.

These meetings will be closed in

accordance with the provisions set forth in

secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and/or proposals and the

discussions could reveal confidential trade

secrets or commercial property such as

patentable material and personal information

concerning individuals associated with the

applications and/or proposals, the disclosure

of which would constitute a clearly

unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance

Programs Nos. 93.855, Immunology, Allergic

and Immunologic Diseases Research; 93.856,

Microbiology and Infectious Diseases

Research, National Institutes of Health.)

Dated: March 5, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–6009 Filed 3–10–97; 8:45 am]

BILLING CODE 4140–01–M

National Institute on Deafness and

Other Communications Disorders;

Notice of Meeting

Notice is hereby given of the NIDCD/

NASA/VA Hearing Aid Improvement

Conference: Facilitating Partnerships for

Technology Transfer, to be held 8:30 am

to 5 pm, May 1–2, 1997, in Masur

Auditorium, National Institutes of

Health, 9000 Rockville Pike, Bethesda

MD 20892.

To register for the meeting ($30

registration fee), please contact Daniel

Winfield, Research Triangle Institute,

P.O. Box 12194, Research Triangle Park,

NC 27709–2194, by phone at 919–541–

6431, by fax at 919–541–6221, or by email at winfield@rti.org.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

contact Mr. Winfield in advance of the

meeting.

Dated: March 5, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–6010 Filed 3–10–97; 8:45 am]

BILLING CODE 4140–01–M

Prospective Grant of Exclusive

License: IL–13 Receptor Specific

Chimeric Proteins and Uses Thereof

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This notice, in accordance

with 35 U.S.C. 209(c)(1) and 37 CFR

404.7(a)(1)(I), announces that the

National Institutes of Health,

Department of Health and Human

Services, is contemplating the grant of

an exclusive world-wide license in the

field of therapeutics to treat cancer to

NeoPharm, Inc. of Delaware to practice

the inventions embodied in U.S. Patent

Application 08/404,685 and

corresponding foreign patent

applications entitled ‘‘IL–13 Receptor

Specific Chimeric Proteins and Uses

Thereof’’ and E–266–94/1 entitled

‘‘Compositions and Methods for

Specifically Targeting Tumors.’’ These

inventions are owned by the

Government of the United States of

America as represented by the

Department of Health and Human

Services and the Pennsylvania State

University.

The prospective exclusive license will

be royalty-bearing and will comply with

the terms and conditions of 35 U.S.C.

209 and 37 CFR 404.7. The prospective

exclusive license may be granted unless

within sixty (60) days from the date of

this published notice, NIH receives

written evidence and argument that

establishes that the grant of the license

would not be consistent with the

requirements of 35 U.S.C. 209 and 37

CFR 404.7.

SUPPLEMENTARY INFORMATION: The patent

application discloses the conjugation of

human interleukin–13 (IL–13) to

genetically engineered bacterial toxin—

pseudomonas exotoxin (PE38QQR)

molecule and its use as a diagnostic and

therapeutic agent. The resulting

chimeric toxin known as hIL13–

PE38QQR binds only to cells expressing

IL–13 receptors. Because of the

chimerica molecule binds only to cells

expressing the IL–13 receptor, i.e.,

tumor cells, the technology can be used

to targets those cells. The improved

specific targeting of this molecule,

which is premised upon the discovery

that tumor cells overexpress IL–13

receptors at extremely high levels,

permits the use of lower dosages of

chimeric molecules to deliver effector

molecules to the targeted tumor cells.

The targeting of this chimeric molecule

has been improved by adding a blocker

of the interleukin–4 receptor. This

invention will be useful in the treatment

of cancer. Specifically, the targeting

method could be used in conjunction

with current methods, e.g.,

chemotherapy, the kill tumor cells

while maintaining healthy cells. To

date, the molecule has been shown to be

effective against a variety of solid tumor

cancers, including adenocarcinoma,

colon cancer, breast cancer, ovarian

cancer, kidney cancer, brain cancer and

AIDS-associated Karposi’s sarcoma.

ADDRESSES: Request for copies of the

patent applications, inquiries,

comments and other materials relating

to the contemplated licences should be

directed to: Jaconda Wagner, J.D.,

Technology Licensing Specialist, Office

of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; Telephone: (301)

496–7735 ext. 284; Facsimile: (301) 402-

0220. A signed Confidentiality

Agreement will be required to receive

copies of the patent applications.

Applications for a license in the field of

use filed in response to this notice will

be treated as objections to the grant of

the contemplated licenses. Only written

comments and/or applications for a

license which are received by NIH on or

before May 12, 1997, will be considered.

Comments and objections submitted to

this notice will not be made available

for public inspection and, to the extent

permitted by law, will not be released

under the Freedom of Information Act.

5 U.S.C. 552.

Dated: Feburary 28, 1997.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 97–6002 Filed 3–10–97; 8:45 am]

BILLING CODE 4140–01–M